Medical composition for treating patients exhibiting cardiac decompensation
AssigneeRELAXERA Pharmazeutische GmbH & Co. KG
InventorThomas Bernd DSCHIETZIG
Life of this patent
Estimating the term…
Abstract
Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject exhibiting cachexia syndrome or cardiac wasting or cardiac decompensation. The application also describes methods of treating cachexia, cardiac wasting and patients exhibiting clinical signs of suffering from cardiac decompensation. Further described is a method of using a patch pump for subcutaneous or intravenous infusion of relaxin or human relaxin-2.
Claims7
A method of treating a subject exhibiting clinical signs of cardiac decompensation comprising the administration of an effective amount of human relaxin-2, wherein said method comprises administering synthetic human relaxin-2 at 10 to 100 μg relaxin-2/kg body weight/day.
A method of treating a subject exhibiting clinical signs of cardiac decompensation when those signs are manifested as dyspnoea or congestion, comprising the administration of an effective amount of human relaxin-2, wherein said method comprises administering synthetic human relaxin-2 at 10 to 100 μg relaxin-2/kg body weight/day.
A method of treating hospice patients exhibiting clinical signs of cardiac decompensation comprising the administration of relaxin-2 to improve their clinical status, wherein said method comprises administering synthetic human relaxin-2 at 10 to 100 μg relaxin-2/kg body weight/day.
Dependencies are inferred from the claim text.